Abstract:Introduction: Immune checkpoints inhibitors (ICIs) are associated with frequent immune-related adverse events (irAEs), but patients with preexisting autoimmune disease (PAD) have been excluded from clinical trials, leaving serious gaps in knowledge. Objective: To evaluate the safety and efficacy of ICIs in PAD patients and cancer and explore the impact of different PAD types and baseline receiving immunosuppressive therapy. Methods: Systematic searches were performed of PubMed, EMBASE, and the Cochrane library from inception through August 2019 for observational studies reporting safety and efficacy data among ICI-treated patients with cancer and PAD. Results: 619 ICI-treated patients with PAD in 14 publications were finally identified. In the random-effects meta analysis, pooled incidence of PAD flares, de novo immune-related adverse events (irAEs) or both of any grade was 60% (95%CI = 52%-68%). Separately, there were 219 and 206 patients experiencing PAD exacerbation and de novo irAEs of any grade, yielding a pooled incidence of 35% (95%CI = 29%-41%) and 33% (95%CI = 24%-42%) respectively. Rheumatoid arthritis was associated with a trend toward higher flare occurrence compared with another individual PADs (RR = 1.25-1.88). A total of 136 patients showed complete or partial response, corresponding to a pooled response rates of 30% (95%CI = 22%-39%). There were no statistical differences between patients with and without immunosuppressive therapy at ICI start regarding flare (RR = 1.08, 95%CI = 0.72-1.62), but a trend toward lower response rates was observed in patients with baseline immunosuppressants (RR = 0.58, 95%CI = 0.26-1.33). Conclusions: Immune toxicities are frequent in ICI-treated patients with PAD but often mild and manageable without discontinuing therapy. ICI treatment are also effective in PAD patients, but close monitoring and multidisciplinary collaboration should be contemplated, especially for those concomitantly receiving immunosuppressant or having rheumatoid arthritis.

Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy

Rheumatic immune-related adverse events induced by immune checkpoint inhibitors

Rheumatologic immune checkpoint inhibitor-related adverse events

[Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)]

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update

Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events

[Side effects of Immune Checkpoint Inhibitors : Diagnostics and Management-an Update]

Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

Immune Checkpoint Inhibitors and Lupus Erythematosus

Immune Checkpoint Inhibitors Therapies in Patients with Cancer and Preexisting Autoimmune Diseases: A Meta-Analysis of Observational Studies.

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors

Acknowledging and addressing real-world challenges to treating immune-related adverse events

Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy

Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach

S1487 Multiple Gastrointestinal Immune Related Adverse Events From Immune Checkpoint Inhibitor Therapy